利用人工智能加速针对不可治疗靶点的药物研发.pdf

1、Michele VendruscoloCentre for Misfolding DiseasesChemistry of Health LaboratoryDepartment of ChemistryUniversity of CambridgeThe Centre for Misfolding DiseasesWe established the Centre for Misfolding Diseases in 2014 with the mission is to discover the molecular origins of misfolding diseases and to

2、 use this knowledge to develop methods to combat them.The Chemistry of Health LaboratorySince 2018,Centre for Misfolding Diseases is hosted in the Chemistry of Health Laboratory in central Cambridge.The Chemistry of Health Laboratory was funded through a UK program to promote early-stage partnership

3、s between academia and industry.The Chemistry of Health IncubatorChemistry of Health hosts a state-of-the art incubator space to facilitate the translation into clinical applications of the research carried out in the University of Cambridge.This Chemistry of Health Incubator hosts spin-out companie

4、s that focus on the development of analytical,diagnostic and therapeutic tools.Alzheimers disease The annual cost of dementia is larger than that of cancer and heart disease combined(UK data).Social costs of dementiaSource:Alzheimers Research TrustDementia receives ten times less research funding th

5、an cancer,despite causing a similar number of deaths and costing twice as much to our healthcare system.Funding dementia researchSource:Alzheimers Research TrustThis approach to drug discovery is repeatable across the 55+protein misfolding diseasesWe are currently focusing on the extension of this s

6、trategy to Parkinsons disease,ALS and type 2 diabetesAlzheimers disease is associated with protein aggregationThe molecular hallmarks of Alzheimers disease are aberrant protein deposits,primarily formed by A(amyloid plaques)and by the protein tau(neurofibrillary tangles).Drug discovery to prevent pr